These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


375 related items for PubMed ID: 31614827

  • 21. Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells.
    Kawauchi K, Ogasawara T, Yasuyama M, Ohkawa Si.
    Blood Cells Mol Dis; 2003; 31(1):11-7. PubMed ID: 12850478
    [Abstract] [Full Text] [Related]

  • 22. Expression of Hippo signaling pathway and Aurora kinase genes in chronic myeloid leukemia.
    Marsola APZC, Simões BP, Palma LC, Berzoti-Coelho MG, Burin SM, de Castro FA.
    Med Oncol; 2018 Jan 31; 35(3):26. PubMed ID: 29387948
    [Abstract] [Full Text] [Related]

  • 23. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF, Moura LG, Tojal I, Ambrósio L, Pinto-Simões B, Hamerschlak N, Calin GA, Ivan C, Covas DT, Kashima S, Castro FA.
    Blood Cells Mol Dis; 2014 Jan 31; 53(1-2):47-55. PubMed ID: 24629639
    [Abstract] [Full Text] [Related]

  • 24. BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia.
    Amarante-Mendes GP, Rana A, Datoguia TS, Hamerschlak N, Brumatti G.
    Pharmaceutics; 2022 Jan 17; 14(1):. PubMed ID: 35057108
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Outcomes of chronic-phase chronic myeloid leukemia beyond first-line therapy.
    Khoury HJ, Bixby DL.
    Leuk Lymphoma; 2015 Mar 17; 56(3):568-76. PubMed ID: 24884315
    [Abstract] [Full Text] [Related]

  • 27. Propofol enhances BCR-ABL TKIs' inhibitory effects in chronic myeloid leukemia through Akt/mTOR suppression.
    Tan Z, Peng A, Xu J, Ouyang M.
    BMC Anesthesiol; 2017 Sep 29; 17(1):132. PubMed ID: 28962554
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.
    Srutova K, Curik N, Burda P, Savvulidi F, Silvestri G, Trotta R, Klamova H, Pecherkova P, Sovova Z, Koblihova J, Stopka T, Perrotti D, Polakova KM.
    Haematologica; 2018 Dec 29; 103(12):2016-2025. PubMed ID: 30049824
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
    Jiang L, Wang H, Zhu X, Liu W, Zhou S, Geng Z, Xiao Y, Zou P, You Y, Li Q, Zhu X.
    Stem Cells Dev; 2019 Nov 15; 28(22):1480-1485. PubMed ID: 31530245
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. TOPK is regulated by PP2A and BCR/ABL in leukemia and enhances cell proliferation.
    Uchida E, Suwa S, Yoshimoto R, Watanabe K, Kasama T, Miura O, Fukuda T.
    Int J Oncol; 2019 May 15; 54(5):1785-1796. PubMed ID: 30864683
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Interferon γ is a STAT1-dependent direct inducer of BCL6 expression in imatinib-treated chronic myeloid leukemia cells.
    Madapura HS, Nagy N, Ujvari D, Kallas T, Kröhnke MCL, Amu S, Björkholm M, Stenke L, Mandal PK, McMurray JS, Keszei M, Westerberg LS, Cheng H, Xue F, Klein G, Klein E, Salamon D.
    Oncogene; 2017 Aug 10; 36(32):4619-4628. PubMed ID: 28368400
    [Abstract] [Full Text] [Related]

  • 36. Successful Preservation of Native BCR::ABL1 in Chronic Myeloid Leukemia Primary Leukocytes Reveals a Reduced Kinase Activity.
    Boni C, Bonifacio M, Vezzalini M, Scaffidi L, Tomasello L, Parker LL, Boscarino D, Paladin D, Krampera M, Sorio C.
    Front Oncol; 2022 Aug 10; 12():904510. PubMed ID: 35756686
    [Abstract] [Full Text] [Related]

  • 37. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
    Yun S, Vincelette ND, Segar JM, Dong Y, Shen Y, Kim DW, Abraham I.
    Clin Lymphoma Myeloma Leuk; 2016 Jun 10; 16(6):e85-94. PubMed ID: 27101984
    [Abstract] [Full Text] [Related]

  • 38. Diagnosing and managing advanced chronic myeloid leukemia.
    Deininger MW.
    Am Soc Clin Oncol Educ Book; 2015 Jun 10; ():e381-8. PubMed ID: 25993200
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Targeting BCR-ABL1-positive leukaemias: a review article.
    Leak S, Horne GA, Copland M.
    Camb Prism Precis Med; 2023 Jun 10; 1():e21. PubMed ID: 38550948
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 19.